Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.

C C Schulman
{"title":"Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.","authors":"C C Schulman","doi":"10.1002/pros.2990250705","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment of locally advanced prostatic cancer is controversial, as there are several possible treatment options. The aims of temporary androgen deprivation prior to radical prostatectomy are to achieve downgrading and downstaging of the tumor, an increase in local control, a decrease in morbidity and operative sequelae, a decrease in the time to progression, and an improvement in survival. A retrospective study has been carried out on 100 patients who underwent radical prostatectomy between 1988 and 1992. Forty patients received androgen deprivation therapy followed by prostatectomy, while the remaining 60 acted as controls, undergoing prostatectomy alone. Treated patients had a 40-50% reduction in prostate volume after 3 months, facilitating dissection of the prostate, reducing intraoperative blood loss, and reducing operation time. Of these 40 treated patients, one third showed clinical downstaging; one patient staged initially as T2/B was downstaged to PT0. The proportion of patients with positive surgical margins was 32% in the group treated preoperatively, compared with 57% in untreated patients. Treated patients also recovered full continence more rapidly after the operation than patients who underwent prostatectomy alone. After androgen blockade, serum PSA levels returned to normal (< 4 ng/ml) in 37 of the 40 patients. Of these patients, 22 had undetectable serum PSA levels (< 0.25 ng/ml), showing a definite reduction in tumor activity. PSA levels after 3 months of neoadjuvant hormonal treatment might play a useful predictive role in selecting patients before radical prostatectomy, since 86% with undetectable PSA had tumors confined to the gland (T2/B2), while patients who still had PSA > 4 ng/ml all had stage T3-T4 tumors. Although downstaging was confirmed pathologically in only 13% of patients, this is of significance when the total number of patients with locally advanced prostate cancer is considered and, therefore, may have implications for survival in the future. Prospective randomized studies should provide conclusive information on the potential benefit of this approach.</p>","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"5 ","pages":"9-14"},"PeriodicalIF":0.0000,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990250705","citationCount":"41","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prostate. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pros.2990250705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

Abstract

The treatment of locally advanced prostatic cancer is controversial, as there are several possible treatment options. The aims of temporary androgen deprivation prior to radical prostatectomy are to achieve downgrading and downstaging of the tumor, an increase in local control, a decrease in morbidity and operative sequelae, a decrease in the time to progression, and an improvement in survival. A retrospective study has been carried out on 100 patients who underwent radical prostatectomy between 1988 and 1992. Forty patients received androgen deprivation therapy followed by prostatectomy, while the remaining 60 acted as controls, undergoing prostatectomy alone. Treated patients had a 40-50% reduction in prostate volume after 3 months, facilitating dissection of the prostate, reducing intraoperative blood loss, and reducing operation time. Of these 40 treated patients, one third showed clinical downstaging; one patient staged initially as T2/B was downstaged to PT0. The proportion of patients with positive surgical margins was 32% in the group treated preoperatively, compared with 57% in untreated patients. Treated patients also recovered full continence more rapidly after the operation than patients who underwent prostatectomy alone. After androgen blockade, serum PSA levels returned to normal (< 4 ng/ml) in 37 of the 40 patients. Of these patients, 22 had undetectable serum PSA levels (< 0.25 ng/ml), showing a definite reduction in tumor activity. PSA levels after 3 months of neoadjuvant hormonal treatment might play a useful predictive role in selecting patients before radical prostatectomy, since 86% with undetectable PSA had tumors confined to the gland (T2/B2), while patients who still had PSA > 4 ng/ml all had stage T3-T4 tumors. Although downstaging was confirmed pathologically in only 13% of patients, this is of significance when the total number of patients with locally advanced prostate cancer is considered and, therefore, may have implications for survival in the future. Prospective randomized studies should provide conclusive information on the potential benefit of this approach.

前列腺切除术前的新辅助雄激素阻断:一项回顾性研究和批判性回顾。
局部晚期前列腺癌的治疗是有争议的,因为有几种可能的治疗方案。根治性前列腺切除术前暂时雄激素剥夺的目的是实现肿瘤的降级和分期,增加局部控制,减少发病率和手术后遗症,减少进展时间,提高生存率。对1988年至1992年间接受根治性前列腺切除术的100例患者进行了回顾性研究。40名患者接受雄激素剥夺治疗后进行前列腺切除术,而其余60名患者作为对照组,仅接受前列腺切除术。治疗后3个月前列腺体积缩小40-50%,有利于前列腺清扫,减少术中出血量,缩短手术时间。在这40名接受治疗的患者中,三分之一的患者表现出临床分期降低;1例患者最初分期为T2/B,降至PT0。术前治疗组手术切缘阳性患者比例为32%,而未治疗组为57%。与单纯行前列腺切除术的患者相比,手术后接受治疗的患者完全尿失禁的恢复速度更快。在雄激素阻断后,40例患者中有37例血清PSA水平恢复正常(< 4 ng/ml)。在这些患者中,22例血清PSA水平检测不到(< 0.25 ng/ml),表明肿瘤活性明显降低。新辅助激素治疗3个月后的PSA水平可能在选择根治性前列腺切除术前的患者中发挥有用的预测作用,因为86%无法检测到PSA的患者肿瘤局限于腺体(T2/B2),而PSA > 4 ng/ml的患者均为T3-T4期肿瘤。虽然病理证实降分期的患者仅占13%,但考虑到局部晚期前列腺癌患者的总数,这一结果具有重要意义,因此可能对未来的生存有影响。前瞻性随机研究应该为这种方法的潜在益处提供结论性信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信